Tue, 08/01/2013 - 12:11
Private equity firm Warburg Pincus has appointed Janet Vergis as an executive-in-residence, a role which will see her support the firm in the identification and evaluation of investment opportunities in the biopharmaceutical sector, particularly in the US.
Vergis (pictured) joins Warburg Pincus with 25 years of pharmaceutical experience and a strong track record of growing businesses.
Most recently, Vergis served as the chief executive officer of OraPharma, a specialty pharmaceutical company focused on oral health, where she led the successful turnaround and subsequent sale of the company to Valeant Pharmaceuticals.
Prior to her role at OraPharma, Vergis managed a USD6bn portfolio at Johnson & Johnson as president of Janssen Pharmaceutica, McNeil Pediatrics, and Ortho-McNeil Neurologics. Vergis also contributed to a number of Johnson & Johnson companies during her career, serving as a member of company management boards for more than 10 years and holding positions of increasing responsibility in research and development, new product development, sales, and marketing.
Bess Weatherman, head of the healthcare group at Warburg Pincus, says: "Janet is an experienced industry leader who brings a wealth of expertise and knowledge to our investment activities. She understands the significant opportunities in the biopharmaceutical sector and will work with us to identify and evaluate companies with the strongest potential for growth and value creation."
Vergis says: "Warburg Pincus and its healthcare group have a well-deserved reputation for backing world-class management teams to build durable growth businesses of scale. I'm excited to be working with the team."
Mon 25/07/2016 - 13:36
Mon 25/07/2016 - 13:28
Fri 22/07/2016 - 08:42
Mon 25/07/2016 - 13:45
Mon 25/07/2016 - 13:42
Mon, 25/Jul/2016 - 14:45
Mon, 25/Jul/2016 - 14:43
Mon, 25/Jul/2016 - 14:28
Mon, 25/Jul/2016 - 13:48
Mon, 25/Jul/2016 - 13:36
Mon, 25/Jul/2016 - 13:28